Across TCGA pan-cancer cohorts, ARHGEF33 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ARHGEF33 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ARHGEF33 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGEF33 expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

SCLC are the cancer types where ARHGEF33 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	III,IV	1.000	0.197	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: ARHGEF33 tumor-vs-normal RNA expression · all ARHGEF33 data types